Multiple low-dose infusions of human umbilical cord blood cells improve cognitive impairments and reduce amyloid-β-associated neuropathology in alzheimer mice

Stem Cells and Development

Volumn 22, Issue 3, 2013, Pages 412-421

  Darlington, Donna ^a   Deng, Juan ^a,b   Giunta, Brian ^a   Hou, Huayan ^a   Sanberg, Cyndy D ^c   Kuzmin Nichols, Nicole ^c   Zhou, Hua Dong ^b   Mori, Takashi ^d   Ehrhart, Jared ^c   Sanberg, Paul R ^a   Tan, Jun ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Saneron CCEL Therapeutics Inc   (United States)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOSIS; BETA AMYLOID PLAQUE; CEREBRAL AMYLOIDOSIS; COGNITIVE DEFECT; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; MAZE TEST; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIAL ARM WATER MAZE TEST; ROTAROD TEST; UMBILICAL CORD BLOOD; WORKING MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANTIGENS, CD45; BRAIN; CELLS, CULTURED; COGNITION; CORD BLOOD STEM CELL TRANSPLANTATION; FEMALE; HUMANS; INFUSIONS, PARENTERAL; MALE; MAZE LEARNING; MEMORY, SHORT-TERM; MICE; MICE, TRANSGENIC; MICROGLIA; MOTOR SKILLS; PLAQUE, AMYLOID; RECOVERY OF FUNCTION; ROTAROD PERFORMANCE TEST;

MUS;

EID: 84872733759     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2012.0345     Document Type: Article

References (66)

1. Giunta B, F Fernandez, WV Nikolic, D Obregon, E Rrap, T Town and J Tan. (2008). Inflammaging as a podrome to Alzheimer's disease. J Neuroinflammation 5:51.
2. Biscaro B, O Lindvall, G Tesco, CT Ekdahl and RM Nitsch. (2012). Inhibition of microglial activation protects hippocampal neurogenesis and improves cognitive deficits in a transgenic mouse model for Alzheimer's disease. Neurodegener Dis 9:187-198.
3. Lue LF, DG Walker and J Rogers. (2001). Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. Neurobiol Aging 22:945-956.
4. Elder GA, MA Gama Sosa and R De Gasperi. (2010). Transgenic mouse models of Alzheimer's disease. Mt Sinai J Med 77:69-81.
5. Holcomb L, MN Gordon, E McGowan, X Yu, S Benkovic, P Jantzen, K Wright, I Saad, R Mueller, et al. (1998). Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes. Nat Med 4:97-100.
6. Schaeffer EL, M Figueiro and WF Gattaz. (2011). Insights into Alzheimer disease pathogenesis from studies in transgenic animal models. Clinics (Sao Paulo) 66 suppl 1: 45-54.
7. Vendrame M, J Cassady, J Newcomb, T Butler, KR Pennypacker, T Zigova, CD Sanberg, PR Sanberg and AE Willing. (2004). Infusion of human umbilical cord blood cells in a rat model of stroke dose-dependently rescues behavioral deficits and reduces infarct volume. Stroke 35:2390-2395.
8. Vendrame M, C Gemma, D de Mesquita, L Collier, PC Bickford, CD Sanberg, PR Sanberg, KR Pennypacker and AE Willing. (2005). Anti-inflammatory effects of human cord blood cells in a rat model of stroke. Stem Cells Dev 14:595-604.
9. Sanberg PR, AE Willing, S Garbuzova-Davis, S Saporta, G Liu, CD Sanberg, PC Bickford, SK Klasko and NS El-Badri. (2005). Umbilical cord blood-derived stem cells and brain repair. Ann N Y Acad Sci 1049:67-83.
10. Taguchi A, T Soma, H Tanaka, T Kanda, H Nishimura, H Yoshikawa, Y Tsukamoto, H Iso, Y Fujimori, et al. (2004). Administration of CD34 + cells after stroke enhances neurogenesis via angiogenesis in a mouse model. J Clin Invest 114:330-338.
11. Cairns K and SP Finklestein. (2003). Growth factors and stem cells as treatments for stroke recovery. Phys Med Rehabil Clin N Am 14 (1 Suppl):S135-S142.
12. El-Badri NS, A Hakki, S Saporta, X Liang, S Madhusodanan, AE Willing, CD Sanberg and PR Sanberg. (2006). Cord blood mesenchymal stem cells: potential use in neurological disorders. Stem Cells Dev 15:497-506.
13. Garbuzova-Davis S, SJ Gografe, CD Sanberg, AE Willing, S Saporta, DF Cameron, T Desjarlais, J Daily, N Kuzmin-Nichols, et al. (2006). Maternal transplantation of human umbilical cord blood cells provides prenatal therapy in Sanfilippo type B mouse model. FASEB J 20:485-487.
14. Henning RJ, JD Burgos, L Ondrovic, P Sanberg, J Balis andMB Morgan. (2006). Human umbilical cord blood progenitor cells are attracted to infarcted myocardium and significantly reduce myocardial infarction size. Cell Transplant 15:647-658.
15. Ende N, R Chen and D Ende-Harris. (2001). Human umbilical cord blood cells ameliorate Alzheimer's disease in transgenic mice. J Med 32:241-247.
16. Newman MB, CD Davis, N Kuzmin-Nichols and PR Sanberg. (2003). Human umbilical cord blood (HUCB) cells for central nervous system repair. Neurotox Res 5: 355-368.
17. Lawlor GF, T Tauchi, K Ohyashiki and T Matsumiya. (2002). Enriched levels of erythropoietin in human umbilical cord blood stimulate hematopoietic progenitor cells. J Biochem Mol Biol Biophys 6:65-70.
18. Simard AR, D Soule, G Gowing, JP Julien and S Rivest. (2006). Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 49:489-502.
19. Hess P, A Altenhö fer, A Salam Khan, N Daryab, K Sik Kim, J Hacker and TA Oelschlaeger. (2004). A salmonella fim homologue in Citrobacter freundii mediates invasion in vitro and crossing of the blood-brain barrier in the rat pup model. Infect Immun 72:5298-5307.
20. Naert G and S Rivest. (2012). Hematopoietic CC-chemokine receptor 2 (CCR2) competent cells are protective for the cognitive impairments and amyloid pathology in a transgenic mouse model of Alzheimer's disease. Mol Med 18:297-313.
21. Wang H, J Sun and H Goldstein. (2008). Human immunodeficiency virus type 1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol 82:7591-7600.
22. Suen Y, SM Lee, J Schreurs, E Knoppel and MS Cairo. (1994). Decreased macrophage colony-stimulating factor mRNA expression from activated cord versus adult mononuclear cells: altered posttranscriptional stability. Blood 84:4269-4277.
23. McGowan E, S Sanders, T Iwatsubo, A Takeuchi, T Saido, C Zehr, X Yu, S Uljon, R Wang, et al. (1999). Amyloid phenotype characterization of transgenic mice overexpressing both mutant amyloid precursor protein and mutant presenilin 1 transgenes. Neurobiol Dis 6:231-244.
24. Nikolic WV, H Hou, T Town, Y Zhu, B Giunta, CD Sanberg, J Zeng, D Luo, J Ehrhart, et al. (2008). Peripherally administered human umbilical cord blood cells reduce parenchymal and vascular beta-amyloid deposits in Alzheimer mice. Stem Cells Dev 17:423-439.
25. Garcia-Alloza M, EM Robbins, SX Zhang-Nunes, SM Purcell, RA Betensky, S Raju, C Prada, SM Greenberg, BJ Bacskai and MP Frosch. (2006). Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis 24:516-524.
26. Jankowsky JL, HH Slunt, T Ratovitski, NA Jenkins, NG Copeland and DR Borchelt. (2001). Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng 17:157-165.
27. Arendash GW, DL King, MN Gordon, D Morgan, JM Hatcher, CE Hope and DM Diamond. (2001). Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res 891:42-53.
28. Alamed J, DM Wilcock, DM Diamond, MN Gordon and D Morgan. (2006). Two-day radial-arm water maze learning and memory task; robust resolution of amyloid-related memory deficits in transgenic mice. Nat Protoc 1:1671-1679.
29. Tan J, T Town, F Crawford, T Mori, A DelleDonne, R Crescentini, D Obregon, RA Flavell and MJ Mullan. (2002). Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat Neurosci 5:1288-1293.
30. Rezai-Zadeh K, D Shytle, N Sun, T Mori, H Hou, D Jeanniton, J Ehrhart, K Townsend, J Zeng, et al. (2005). Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25:8807-8814.
31. Walsh DM, BP Tseng, RE Rydel, MB Podlisny and DJ Selkoe. (2000). The oligomerization of amyloid beta-protein begins intracellularly in cells derived from human brain. Biochemistry 39:10831-10839.
32. Lesné S, MT Koh, L Kotilinek, R Kayed, CG Glabe, A Yang, M Gallagher and KH Ashe. (2006). A specific amyloid-beta protein assembly in the brain impairs memory. Nature 440:352-357.
33. Lee HJ, JK Lee, H Lee, JE Carter, JW Chang, W Oh, YS Yang, JG Suh, BH Lee, HK Jin and JS Bae. (2012). Human umbilical cord blood-derived mesenchymal stem cells improve neuropathology and cognitive impairment in an Alzheimer's disease mouse model through modulation of neuroinflammation. Neurobiol Aging 33:588-602.
34. Koyama A, OI Okereke, T Yang, D Blacker, DJ Selkoe and F Grodstein. (2012). Plasma amyloid-beta as a predictor of dementia and cognitive decline: a systematic review and meta-analysis. Arch Neurol 69:824-831.
35. Benzing WC, JR Wujek, EK Ward, D Shaffer, KH Ashe, SG Younkin and KR Brunden. (1999). Evidence for glialmediated inflammation in aged APP(SW) transgenic mice. Neurobiol Aging 20:581-589.
36. Bornemann KD and M Staufenbiel. (2000). Transgenic mouse models of Alzheimer's disease. Ann N Y Acad Sci 908:260-266.
37. Selkoe DJ. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 81:741-766.
38. DeMattos RB, KR Bales, DJ Cummins, SM Paul and DM Holtzman. (2002). Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295:2264-2267.
39. Malinin NL, S Wright, P Seubert, D Schenk and I Griswold-Prenner. (2005). Amyloid-beta neurotoxicity is mediated by FISH adapter protein and ADAM12 metalloprotease activity. Proc Natl Acad Sci USA 102:3058-3063.
40. Christie R, M Yamada, M Moskowitz and B Hyman. (2001). Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy. Am J Pathol 158:1065-1071.
41. Eikelenboom P and WA van Gool. (2004). Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J Neural Transm 111:281-294.
42. Rozemuller AJ, WA van Gool and P Eikelenboom. (2005). The neuroinflammatory response in plaques and amyloid angiopathy in Alzheimer's disease: therapeutic implications. Curr Drug Targets CNS Neurol Disord 4:223-233.
43. Bates KA, G Verdile, QX Li, D Ames, P Hudson, CL Masters and RN Martins. (2009). Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Mol Psychiatry 14:469-486.
44. Townsend KP, T Town, T Mori, LF Lue, D Shytle, PR Sanberg, D Morgan, F Fernandez, RA Flavell and J Tan. (2005). CD40 signaling regulates innate and adaptive activation of microglia in response to amyloid beta-peptide. Eur J Immunol 35:901-910.
45. Lixian J, S Saporta, N Chen, CD Sanberg, PR Sanberg and A Willing. (2010). The effects of human umbilical cord blood cells on survival and cytokine production by post-ischemic astrocytes in vitro. Stem Cell Rev 6:523-531.
46. Lue LF and DG Walker. (2002). Modeling Alzheimer's disease immune therapy mechanisms: interactions of human postmortem microglia with antibody-opsonized amyloid beta peptide. J Neurosci Res 70:599-610.
47. Suo Z, J Tan, A Placzek, F Crawford, C Fang and M Mullan. (1998). Alzheimer's beta-amyloid peptides induce inflammatory cascade in human vascular cells: the roles of cytokines and CD40. Brain Res 807:110-117.
48. Naert G and S Rivest. (2011). The role of microglial cell subsets in Alzheimer's disease. Curr Alzheimer Res 8: 151-155.
49. Tan J, T Town and M Mullan. (2002). CD40-CD40L interaction in Alzheimer's disease. Curr Opin Pharmacol 2: 445-451.
50. Giunta B, KP Figueroa, T Town and J Tan. (2009). Soluble CD40 ligand in dementia. Drugs Future 34:333-340.
51. Giunta B, K Rezai-Zadeh and J Tan. (2010). Impact of the CD40-CD40L dyad in Alzheimer's disease. CNS Neurol Disord Drug Targets 9:149-155.
52. Town T, J Tan and M Mullan. (2001). CD40 signaling and Alzheimer's disease pathogenesis. Neurochem Int 39: 371-380.
53. Calingasan NY, HA Erdely and CA Altar. (2002). Identification of CD40 ligand in Alzheimer's disease and in animal models of Alzheimer's disease and brain injury. Neurobiol Aging 23:31-39.
54. Togo T, H Akiyama, H Kondo, K Ikeda, M Kato, E Iseki and K Kosaka. (2000). Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res 885:117-121.
55. Riordan NH, K Chan, AM Marleau and TE Ichim. (2007). Cord blood in regenerative medicine: do we need immune suppression? J Transl Med 5:8.
56. Sanchez-Ramos JR, S Song, SG Kamath, T Zigova, A Willing, F Cardozo-Pelaez, T Stedeford, M Chopp and PR Sanberg. (2001). Expression of neural markers in human umbilical cord blood. Exp Neurol 171:109-115.
57. Rainsford E and DJ Reen. (2002). Interleukin 10, produced in abundance by human newborn T cells, may be the regulator of increased tolerance associated with cord blood stem cell transplantation. Br J Haematol 116:702-709.
58. Paresce DM, RN Ghosh and FR Maxfield. (1996). Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron 17: 553-565.
59. Borlongan CV, M Hadman, CD Sanberg and PR Sanberg. (2004). Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke. Stroke 35:2385-2389.
60. Paresce DM, H Chung and FR Maxfield. (1997). Slow degradation of aggregates of the Alzheimer's disease amyloid betaprotein by microglial cells. J Biol Chem 272:29390-29397.
61. Chung H, MI Brazil, TT Soe and FR Maxfield. (1999). Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid beta-peptide by microglial cells. J Biol Chem 274:32301-32308.
62. Imrich H and K Harzer. (2001). On the role of peripheral macrophages during active experimental allergic encephalomyelitis (EAE). J Neural Transm 108:379-395.
63. Priller J, A Flugel, T Wehner, M Boentert, CA Haas, M Prinz, F Fernandez-Klett, K Prass, I Bechmann, et al. (2001). Targeting gene-modified hematopoietic cells to the central nervous system: use of green fluorescent protein uncovers microglial engraftment. Nat Med 7:1356-1361.
64. Town T, M Vendrame, A Patel, D Poetter, A DelleDonne, T Mori, R Smeed, F Crawford, T Klein, J Tan and M Mullan. (2002). Reduced Th1 and enhanced Th2 immunity after immunization with Alzheimer's beta-amyloid(1-42). J Neuroimmunol 132:49-59.
65. Town T, V Nikolic and J Tan. (2005). The microglial " activation" continuum: from innate to adaptive responses. J Neuroinflammation 2:24.
66. Town T, J Tan, RA Flavell and M Mullan. (2005). T-cells in Alzheimer's disease. Neuromolecular Med 7:255-264.